Navigation Links
Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call
Date:4/14/2011

SAN DIEGO, April 14, 2011 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ: GPRO) announced today that the Company will release its first quarter 2011 financial results on Thursday, April 28, 2011 at approximately 4:00 pm Eastern Time (ET). The announcement will be followed by a conference call with management at 4:30 pm ET.  

The conference call will be webcast live and may be accessed on the investors section of the Company's web site at www.gen-probe.com.  An archived version of the webcast will be available on the same web site for at least 90 days. A telephone replay also will be available for 24 hours after the call ends. To access the replay, please call 800-839-5573 (US) or 402-220-2075 (international).

About Gen-Probe

Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe has approximately 28 years of expertise in nucleic acid testing (NAT), and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements.  Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including our most recent Form 10-K, and all subsequent periodic filings.  We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe Reports Financial Results for the Fourth Quarter and Full Year 2010
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call
3. Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference
4. Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash
5. Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
6. Gen-Probe to Acquire Prodesse, Leader in Molecular Testing for Respiratory Infectious Diseases, for $60 Million in Cash Plus Potential Milestone Payments
7. Gen-Probe to Consolidate Industrial Assets Into New, Independent Company
8. Gen-Probe to Webcast Four Upcoming Investor Presentations
9. Gen-Probe to Webcast Two Upcoming Investor Presentations
10. Gen-Probe Completes Acquisition of Tepnel Life Sciences
11. Gen-Probe to Webcast Two Upcoming Investor Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach ... during the forecast period of 2016 to 2021 dominated by immunohistochemistry ... the largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... across 225 pages, profiling 10 companies and supported with 181 tables ...
(Date:11/30/2016)... 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the ... excited to announce the formation of EyGen, Ltd. ... ophthalmology assets through proof of concept. EyGen,s lead ... Portage Pharmaceuticals Limited and being developed for topical ... anterior segment diseases. This agent has the potential ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 /PRNewswire/ ... of genomic services and solutions with cutting edge next-generation ... has completed a USD $75 Million [515 Million RMB] ... CMB International Capital Management ( Shenzhen ) ... Ltd. ("SDIC Innovation") and Shanghai Sigma Square Investment Center ...
Breaking Biology Technology:
(Date:11/17/2016)... Nov. 17, 2016  AIC announces that it has just released a new white ... require high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), a ... challenging operating environments, announced its results for the third ... conference call to discuss these results on November 15, ... Key Recent Accomplishments The ... Vislink Communication Systems. The purchase is expected to close ...
Breaking Biology News(10 mins):